https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-12-23 / Neuro Oncol 2022 Dec;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-12-23 / Neuro Oncol 2022 Dec;2022-12-23 00:00:002022-12-23 00:00:00Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination (DCVax-L) in glioblastoma: breakthrough or fata morgana?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-12-04 / Cancer Med 2023 Mar;12(6):7207-7221
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-12-04 / Cancer Med 2023 Mar;12(6):7207-72212022-12-04 00:00:002023-05-30 16:29:12Dendritic cell vaccines improve the glioma microenvironment: Influence, challenges, and future directions
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-09-06 / Molecules 2022 Sep;27(18)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-09-06 / Molecules 2022 Sep;27(18)2022-09-06 00:00:002022-09-06 00:00:00Oncolytic Newcastle Disease Virus Co-Delivered with Modified PLGA Nanoparticles Encapsulating Temozolomide against Glioblastoma Cells: Developing an Effective Treatment Strategy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-03-08 / Expert Rev Vaccines 2022 Apr;21(4):513-531
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-03-08 / Expert Rev Vaccines 2022 Apr;21(4):513-5312022-03-08 00:00:002022-03-08 00:00:00A comprehensive update to Dendritic Cell therapy for glioma: a systematic review and meta-analysis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-02-16 / Genes Immun 2022 Feb;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-02-16 / Genes Immun 2022 Feb;2022-02-16 00:00:002022-02-21 07:49:56Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-02-04 / Curr Oncol 2022 Feb;29(2):881-891
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-02-04 / Curr Oncol 2022 Feb;29(2):881-8912022-02-04 00:00:002023-01-31 12:41:45Delayed Effect of Dendritic Cells Vaccination on Survival in Glioblastoma: A Systematic Review and Meta-Analysis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-01-19 / Genes Immun 2022 02;23(1):1-11
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-01-19 / Genes Immun 2022 02;23(1):1-112022-01-19 00:00:002022-01-19 00:00:00Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-12-03 / Clin Cancer Res 2021 Dec;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-12-03 / Clin Cancer Res 2021 Dec;2021-12-03 00:00:002021-12-03 00:00:00A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-11-02 / Front Immunol 2021;12:770390
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-11-02 / Front Immunol 2021;12:7703902021-11-02 00:00:002021-11-02 00:00:00Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-11-01 / Clin Neuropharmacol 2021 Nov-Dec 01;44(6):216-221
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-11-01 / Clin Neuropharmacol 2021 Nov-Dec 01;44(6):216-2212021-11-01 00:00:002021-11-01 00:00:00The Efficacy of Dendritic Cell Vaccine for Newly Diagnosed Glioblastoma: A Meta-analysis of Randomized Controlled Studies
